Research Preview for IAS 2015 (Part 1): Broadly Neutralizing Antibodies; START Study; Cure Updates; and More
July 14, 2015
TheBodyPRO.com is getting ready for the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), which starts Sunday, July 19, 2015. Many of the world's leading HIV and Hepatitis experts will gather in Vancouver, Canada, to present new research and data. And we'll be providing on-the-ground reporting and coverage as the conference takes place, and continually after the conference itself has wrapped up. Before we get there, here's part one of our preview on the sessions and science that's most worth looking forward to.
New Approaches to Using Broadly Neutralizing Antibodies for HIV Prevention
Enthusiasm in the vaccine field has been refreshed recently with the recent discovery of more broadly neutralizing antibodies (bNAbs). This session will provide an introduction and highlight key developments, as well as an update on NIH study VRC601, which tests the bNAb VRC01's ability to protect against HIV infection.
The Strategic Timing of AntiRetroviral Treatment (START) Study: Results and Their Implications
We heard a lot about the START study ending early back in May, after a data safety and monitoring board found compelling evidence that starting treatment immediately far outweighed the risks of delaying. Now we'll see the full study results presented, as well as a discussion on the wider implications for the future of treatment.
Progress and Challenges in HIV Prevention: Vaccine and Non-Vaccine Approaches
Anthony Fauci, M.D., will be providing a special session to discuss recent progress and challenges in the field of HIV prevention. Fauci will discuss emerging synergies between vaccine and non-vaccine prevention strategies, and specifically talk about the critical role of pre-exposure prophylaxis (PrEP).
Immune Activation in HIV: Friends or Foe?
We hear a lot about immune activation, and how these markers of inflammation persist in people living with HIV despite being on successful treatment. This session will delve a little deeper into understanding the dual role these markers may play.
TasP (Treatment as Prevention): Just Do It
The title says it all. We've seen overwhelming evidence that treatment as prevention works -- for those living with HIV who gain the benefits of starting antiretroviral therapy early and on a community level where having an undetectable viral load adds another layer of prevention. In this session, we'll see the final results of HPTN 052.
Achieving HIV Remission: Reconciling Disparate Strategies
In our latest HIV cure update, we'll be hearing the status on "shock and kill" approaches, targeting the latent reservoir with a potent Tat inhibitor, as well as gene therapy. There will also be discussion on how to combine strategies to achieve a cure, or sustained HIV remission.
Microbiome: the Good and the Bad for HIV
The microbiome is still not fully understood, yet the gut and digestive issues are especially important for people living with HIV. This session should be interesting as it analyzes some of the current gut issues in HIV.
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
This article was provided by TheBodyPRO. It is a part of the publication The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.